Jeffrey Dunn, MD
Academic Appointments
- Clinical Professor, Neurology & Neurological Sciences
Key Documents
Contact Information
-
Clinical Offices
Dept of Neurology 300 Pasteur Dr Rm A343 MC 5325 Stanford, CA 94305 Tel Work (650) 736-4310 Fax (650) 725-7459
- Academic Offices
Personal Information Tel (650) 736-4310Alternate Contact Ana Mezynski Administrative Associate Tel Work 650.736.4310Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Multiple Sclerosis
- Neuromyelitis Optica
- Transverse Myelitis
- Neurology
Administrative Appointments
- Director, Neurology Clerkship Program (2009 - present)
- Chair, MS Education Workgroup, Multiple Sclerosis Section; American Academy of Neurology (2011 - present)
- Councilor, Executive Committee, Multiple Sclerosis Section; American Academy of Neurology (2010 - present)
- Co-Director, Stanford Multiple Sclerosis Center (2008 - present)
Honors and Awards
- Top Doctors, US News & World Report (2011-2012)
- Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)
- Successful Recruitment Award, top US percentage, Association of University Professors of Neurology (2012)
- Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
- AUPN Neurology Recruitment Award (highest percentage in U.S.), Association of University Professors of Neurology (2011)
- Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
Professional Education
| Board Certification: | Neurology, American Board of Psychiatry and Neurology (1994) |
| Residency: | University of Washington Medical Center, WA USA (1993) |
| Internship: | Eastern VA Medical School, VA USA (1990) |
| Medical Education: | Temple University School of Medicine, PA USA (1989) |
| Residency: | University of Washington, Neurology (1993) |
| M.D.: | Temple University, Medicine (1989) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Editorial Board, International
- PACTRIMS Member
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Translational research in the human application of emerging immunotherapies for neurological disease, focusing on Multiple Sclerosis, CIS, transverse myelitis and Neuromyelitis Optica (NMO). Collaborative research with Stanford and extramural scientific faculty to identify biomarkers of disease activity and treatment response in humans. Clinical trials to assess efficacy of emerging treatments for MS, CIS and NMO, recently including trials of alemtuzumab, oral sphingosine 1 phosphate inhibition, NIH CombiRx and Biomarkers, Subcutaneous Tovaxin in Subjects with CIS, Subcutaneous Daclizumab, NC-100 Novantrone induction, dose ranging GA pilot trial, natalizumab safety and tolerability monitoring; and sub-investigation of Fampridine SR (approved 1/10 brand name Ampyra).
Clinical Trials
- Not Recruiting Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study
- Recruiting An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
- Recruiting Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
- Not Recruiting An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
- Not Recruiting A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Publications
- Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein Multiple Sclerosis. 2012; (4): 398-408
- Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012; (4): 398-408
- Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis Current Research Medical Opinion. 2011; (7): 1415-1423
- Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011; (7): 1415-23
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010; (4): 381-90
- Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2010; (4): 433-40
Help